# Aspirin for Exercise in Multiple Sclerosis (ASPIRE)

> **NCT03824938** · PHASE3 · COMPLETED · sponsor: **Columbia University** · enrollment: 60 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Aspirin 650mg Oral Capsule
- **DRUG:** Acetaminophen Tablet 650mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03824938
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-30
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-02-28
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2023-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03824938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03824938, "Aspirin for Exercise in Multiple Sclerosis (ASPIRE)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03824938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*